Skip to main
HSCS

HSCS Stock Forecast & Price Target

HSCS Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

HeartSciences Inc. is enhancing its financial outlook by demonstrating improved earnings per share (EPS) estimates, with a notable upward adjustment from $(4.17) to $(3.76) for FY26, reflecting a better share count. The company is also on a promising trajectory of cost management, leading to an additional increase in EPS estimates from $(3.76) to $(3.28) based on reduced expenses, while expanding its average shares outstanding to 3.2 million. Furthermore, HeartSciences is positioned to capitalize on a significant market opportunity by developing scalable AI-ECG diagnostic solutions, suggesting the potential for recurring revenue through its innovative platform akin to an app store model.

Bears say

HeartSciences Inc. is facing a negative outlook primarily due to a significant lack of visibility regarding the timing of commercial revenues, leading to downward revisions in revenue estimates for fiscal years 2026 and 2027, with projections of only $0.0 million and $0.4 million, respectively. Additionally, while operating expenses were closely aligned with estimates at $2.1 million, the company is encumbered by multiple risks including liquidity concerns, regulatory approval failures, and challenges in product commercialization which could hinder financial stability. Compounding these issues are external factors such as investor sentiment and shifting priorities in healthcare that may negatively impact the company's growth trajectory and overall market performance.

HSCS has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Heart Test Laboratories Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Heart Test Laboratories Inc (HSCS) Forecast

Analysts have given HSCS a Strong Buy based on their latest research and market trends.

According to 1 analysts, HSCS has a Strong Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Heart Test Laboratories Inc (HSCS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.